Atreca Q3 EPS $(0.74) Down From $(0.66) YoY
Atreca (NASDAQ:BCEL) reported quarterly losses of $(0.74) per share. This is a 12.12 percent decrease over losses of $(0.66) per share from the same period last year.
64 Biggest Movers From Yesterday
Gainers
ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the company filed a mixed shelf offering on Friday after the close.
40 Stocks Moving In Monday’s Mid-Day Session
Gainers
ABVC BioPharma, Inc. (NASDAQ: ABVC) shares jumped 250% to $8.91 on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the company filed a mixed shelf offering on Friday after the close.
Atreca Ink Licensing Pact With Gates Research On Malaria Antibody
Atreca Inc (NASDAQ:BCEL) has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501…
Atreca Q2 EPS $(0.72) Down From $(0.71) YoY
Atreca (NASDAQ:BCEL) reported quarterly losses of $(0.72) per share. This is a 1.41 percent decrease over losses of $(0.71) per share from the same period last year.
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam’s Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)